About us

Renowned, innovative Pharmaceuticals.

Constantly building upon our extensive knowledge of the Chinese market, our company runs its own research and development teams, which are capable of continuously meeting the challenges of complex Multi Stage Chemistry.

Top quality since 1995.

Since starting off in 1995 as the first Active Pharma Ingredient manufacturer in Hong Kong, we are proud of our constant growth.

1995
Foundation of PEN TSAO in Hong Kong as private owned company.
1996
Operations moved to Shanghai.
2004
First foreign enterprise in Shanghai granted GMP-status.
2012
First WHO pre-qualified supplier of MDR-tuberculosis drugs.
2017
New site in Pinghu (Zhejiang province) acquired.
2019
Foundation of RODALLIS BioPharma Co. Ltd.
2024
Rodallis becomes operational.

Recent Inspections

SFDA China
Regular flying inspections (last March 2023)
WHO Prequalification
February 2021
EU Written Confirmation
March 2021, July 2022
Clients On Site/Online Audits
2 in 2020, 3 in 2021, 3 in 2022 (Online)

Partners from three countries.

While under German management, the PEN TSAO Group is owned by private partners from Hong Kong, Switzerland and Germany.

Private Partners

PEN TSAO Chemical Industry Ltd. Hongkong

PEN TSAO Chem & Pharm Industry Co., Ltd. Baoshan, Shanghai (China)

RODALLIS BioPharma Co., Ltd. Pinghu, Zhejiang (China)

Operating in three locations.

Besides our original location in Hong Kong, where the PEN TSAO Group was founded and is managed from, our production locations are divided into two seperate sites:

Baoshan site (Shanghai)

Area of 11.000 m²
35 km from Hongqiao Hub
45 km from Pudong Intl. Airport
56 m³ reactor volume, completed with solid/liquid separation, over 800 different compounds synthezised and more than 150 of them commercialized
Waste water and waste gas treatment facilities

Open in Google Maps

Pinghu site (Dushan Port, Zhejiang)

Area of 33.300 m² (+ 16.600 m² for extension)
65 km from Hongqiao Hub
90 km from Pudong Intl. Airport
3 km south of Shanghai Jinshan Chemical Park
API production: 218 m³ reactor volume,
Multi Purpose OSD facility: 70 t Formulations

Open in Google Maps